Altshuler, D, Hirschhorn, JN, Klannemark, M, et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26, 76–80.
American Diabetes Association (2004) Screening for type 2 diabetes. Diabetes Care 27, S11–S14.
Brandt, JM, Djouadi, F & Kelly, DP (1998) Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 273, 23786–23792.
Darimont, C, Gradoux, N, Cumin, F, Baum, HP & De Pover, A (1998) Differential regulation of intestinal and liver fatty acid-binding proteins in human intestinal cell line (Caco-2): role of collagen. Exp Cell Res 244, 441–447.
Desvergne, B & Wahli, W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20, 649–688.
Ek, J, Andersen, G, Urhammer, SA, et al. (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44, 1170–1176.
Frederiksen, L, Brodbaek, K, Fenger, M, Jorgensen, T, Borch-Johnsen, K, Madsbad, S & Urhammer, SA (2002) Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 87, 3989–3992.
Giorgino, F, Laviola, L & Eriksson, JW (2005) Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand 183, 13–30.
Gonzalez-Sanchez, JL, Serrano Rios, M, Fernandez Perez, C, Laakso, M & Martinez Larrad, MT (2002) Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 147, 495–501.
Haffner, SM, Miettinen, H & Stern, MP (1997) The homeostasis model in the San Antonio Heart Study. Diabetes Care 20, 1087–1092.
Hampe, J, Shaw, SH, Saiz, R, et al. (1999) Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 65, 1647–1655.
Hertz, R, Bishara-Shieban, J & Bar-Tana, J (1995) Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 270, 13470–13475.
Issemann, I, Prince, R, Tugwood, J & Green, S (1992) A role for fatty acids and liver fatty acid binding protein in peroxisome proliferation? Biochem Soc Trans 20, 824–827.
Jacob, S, Stumvoll, M, Becker, R, et al. (2000) The PPARgamma2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 32, 413–416.
Jiang, C, Ting, AT & Seed, B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82–86.
Koch, M, Rett, K, Maerker, E, Volk, A, Haist, K, Deninger, M, Renn, W & Haring, HU (1999) The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 42, 758–762.
Lahti-Koski, M, Pietinen, P, Mannisto, S & Vartiainen, E (2000) Trends in waist-to-hip ratio and its determinants in adults in Finland from 1987 to 1997. Am J Clin Nutr 72, 1436–1444.
Li, S, Chen, W, Srinivasan, SR, Boerwinkle, E & Berenson, GS (2003) The peroxisome proliferator-activated receptor-gamma2 gene polymorphism (Pro12Ala) beneficially influences insulin resistance and its tracking from childhood to adulthood: the Bogalusa Heart Study. Diabetes 52, 1265–1269.
Li, Y & Lazar, MA (2002) Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2. Mol Endocrinol 16, 1040–1048.
Luan, J, Browne, PO, Harding, AH, Halsall, DJ, O'Rahilly, S, Chatterjee, VK & Wareham, NJ (2001) Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50, 686–689.
Mascaro, C, Acosta, E, Ortiz, JA, Marrero, PF, Hegardt, FG & Haro, D (1998) Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem 273, 8560–8563.
Nitz, I, Doring, F, Schrezenmeir, J & Burwinkel, B (2005) Identification of new acyl-CoA binding protein transcripts in human and mouse. Int J Biochem Cell Biol 37, 2395–2405.
Poirier, O, Nicaud, V, Cambien, F & Tiret, L (2000) The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: the European Atherosclerosis Research Study II. J Mol Med 78, 346–351.
Roden, M, Price, TB, Perseghin, G, Petersen, KF, Rothman, DL, Cline, GW & Shulman, GI (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97, 2859–2865.
Schoonjans, K, Peinado-Onsurbe, J, Lefebvre, AM, Heyman, RA, Briggs, M, Deeb, S, Staels, B & Auwerx, J (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J 15, 5336–5348.
Schoonjans, K, Watanabe, M, Suzuki, H, Mahfoudi, A, Krey, G, Wahli, W, Grimaldi, P, Staels, B, Yamamoto, T & Auwerx, J (1995) Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 270, 19269–19276.
Schrezenmeir, J, Weber, P, Probst, R, Biesalski, HK, Luley, C, Prellwitz, W, Krause, U & Beyer, J (1992) Postprandial pattern of triglyceride-rich lipoprotein in normal-weight humans after an oral lipid load: exaggerated triglycerides and altered insulin response in some subjects. Ann Nutr Metab 36, 186–196.
Sewter, C & Vidal-Puig, A (2002) PPARgamma and the thiazolidinediones: molecular basis for a treatment of ‘Syndrome X’? Diabetes Obes Metab 4, 239–248.
Spiegelman, BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507–514.
Stefan, N, Fritsche, A, Haring, H & Stumvoll, M (2001) Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene. Diabetes 50, 1143–1148.
Stumvoll, M & Haring, H (2002) Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARgamma2? Diabetologia 45, 152–153.
Tan, GD, Neville, MJ, Liverani, E, Humphreys, SM, Currie, JM, Dennis, L, Fielding, BA & Karpe, F (2006) The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia 49, 158–168.
Temelkova-Kurktschiev, THM, Chinetti, G, Zawadzki, C, Haulon, S, Kubaszek, A, Koehler, C, Leonhardt, W, Staels, B & Laakso, M (2004) AlAla12Alala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab 89, 4238–4242.
Tontonoz, P, Hu, E, Graves, RA, Budavari, AI & Spiegelman, BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8, 1224–1234.
Trayhurn, P & Wood, IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92, 347–355.
Vaccaro, O, Mancini, FP, Ruffa, G, Sabatino, L, Iovine, C, Masulli, M, Colantuoni, V & Riccardi, G (2002) Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) gamma2 gene in healthy individuals. Clin Endocrinol (Oxf) 57, 481–486.
Valve, R, Sivenius, K, Miettinen, R, Pihlajamaki, J, Rissanen, A, Deeb, SS, Auwerx, J, Uusitupa, M & Laakso, M (1999) Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84, 3708–3712.
Vänttinen, M, Nuutila, P, Pihlajamaki, J, et al. (2005) The effect of the Ala12 allele of the peroxisome proliferator-activated receptor-gamma2 gene on skeletal muscle glucose uptake depends on obesity: a positron emission tomography study. J Clin Endocrinol Metab 90, 4249–4254.
Vidal-Puig, AJ, Considine, RV, Jimenez-Linan, M, Werman, A, Pories, WJ, Caro, JF & Flier, JS (1997) Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99, 2416–2422.
World Health Organization (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 854, 1–452.
Yamamoto, Y, Hirose, H, Miyashita, K, Nishikai, K, Saito, I, Taniyama, M, Tomita, M & Saruta, T (2002) PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism 51, 1407–1409.
Yamauchi, T, Kamon, J, Waki, H, et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7, 941–946.
Yen, CJ, Beamer, BA, Negri, C, Silver, K, Brown, KA, Yarnall, DP, Burns, DK, Roth, J & Shuldiner, AR (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241, 270–274.
Yu, GS, Lu, YC & Gulick, T (1998) Co-regulation of tissue-specific alternative human carnitine palmitoyltransferase Ibeta gene promoters by fatty acid enzyme substrate. J Biol Chem 273, 32901–32909.